MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Transgenomic Company Profile (NASDAQ:TBIO)

Consensus Ratings for Transgenomic (NASDAQ:TBIO) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (1,310.69% upside)

Analysts' Ratings History for Transgenomic (NASDAQ:TBIO)
Show:
DateFirmActionRatingPrice TargetActions
8/14/2015Craig HallumLower Price TargetBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Transgenomic (NASDAQ:TBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/24/2016Q116($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.27)($0.18)$6.65 million$4.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.41)($0.30)$7.10 million$7.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.52)($0.36)$6.80 million$6.51 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2015Q414($0.56)($0.77)$6.20 million$7.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014($0.58)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.47)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014($0.36)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/20132Q13($0.03)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/20131Q13($0.03)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/20134Q12($0.03)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Transgenomic (NASDAQ:TBIO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Transgenomic (NASDAQ:TBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Transgenomic (NASDAQ:TBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/22/2014Leroy C KoppMajor ShareholderSell413,050$3.70$1,528,285.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2013Leroy C KoppMajor ShareholderBuy9,000$0.39$3,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Transgenomic (NASDAQ:TBIO)
DateHeadline
06/29/16 06:39 PMTransgenomic Incorporated (NASDAQ:TBIO) Short Interest Decreased By 37.88% - Engelwood Daily
06/25/16 10:22 AMTransgenomic Incorporated (NASDAQ:TBIO) Short Interest Increased By 9.88% - Engelwood Daily
06/23/16 07:26 PMTransgenomic : Accelerates Commercialization of ICE COLD-PCR ICP amid Plans to Expand Cancer Product Line Ten-Fold
06/17/16 06:25 PMStrong Buy Calls Count For Transgenomic, Inc. (NASDAQ:TBIO) At 1 - Investor Newswire
06/17/16 06:25 PMInvestor News: Transgenomic Inc (NASDAQ:TBIO) faces Investigation - GroundReport
06/16/16 11:07 AMInvestor News: Transgenomic Inc (NASDAQ:TBIO) faces Investigation
06/15/16 09:22 AMTransgenomic (TBIO) Announces Expansion of ICE COLD-PCR (ICP)-Powered Cancer Assays - StreetInsider.com
06/14/16 06:39 AMTransgenomic Accelerates Commercialization of ICE COLD-PCR (ICP) Amid Plans To Expand Cancer Product Line Ten-Fold - [at noodls] - TBIO's ICP Cancer Product Line to Include More than 200 Exons/Mutations by 2018 OMAHA, NE (June 14, 2016) - Transgenomic, Inc. (TBIO), (NASDAQ: TBIO), today announced plans to expand its ICE COLD-PCR (ICP)-powered ...
06/09/16 07:13 PMInvestigation of Transgenomic Inc (NASDAQ:TBIO) for Investors Announced - Digital Journal
06/07/16 04:17 PMTRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Oblig -
06/07/16 09:34 AMTransgenomic (TBIO) to Present New ICE COLD-PCR Tech Data at ASCO - StreetInsider.com
06/07/16 06:28 AMTransgenomic Releases New Data at ASCO 2016 Conference Confirming Concordance of ICE COLD-PCR (ICP) Liquid and Tissue Biopsies - [at noodls] - Educational Handouts Present Additional Data Confirming Concordance and Utility of ICP Liquid Biopsy Results; Unveil New Data Highlighting Speed and Efficiency of Multiplexed ICP Used with Veriti Thermal ...
06/07/16 06:15 AMTransgenomic Releases New Data at ASCO 2016 Confirming Concordance of ICE COLD-PCR (ICP) Liquid and Tissue Biopsies - [Business Wire] - Transgenomic, Inc. , , today announced that it is unveiling new data at the American Society for Clinical Oncology 2016 Annual Meeting further confirming the utility, speed and efficiency of its ICE COLD-PCR™ technology for liquid biopsy detection of tumor mutations.
06/02/16 09:55 AMInsiders Are Gradually Buying Transgenomic Inc. (NASDAQ:TBIO) - HNN - Insiders Are Gradually Buying Transgenomic Inc. (NASDAQ:TBIO)HNNAccording to the latest SEC filings, insiders at Transgenomic Inc. (NASDAQ:TBIO) have increased their position in the stock by 114.50% over the past 6 months. Insiders now own 18.61% of total outstanding shares. There are both legal and illegal types ...and more »
06/01/16 09:43 AMRevenue Update on Transgenomic Inc(NASDAQ:TBIO) - Trade Calls - Revenue Update on Transgenomic Inc(NASDAQ:TBIO)Trade CallsTransgenomic Inc(NASDAQ:TBIO) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 24, 2016. Earnings per share were $-0.10. Transgenomic Inc (TBIO) shares turned negative on Fridays trading ...
05/26/16 10:18 AMTransgenomic, Inc. :TBIO-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 -
05/24/16 06:16 AMTransgenomic Reports First Quarter 2016 Financial Results - [at noodls] - Conference Call to be Held at 9:00 AM Eastern Time Today Omaha, Neb. (May 24, 2016) - Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the first quarter ended March 31, 2016, and ...
05/24/16 06:08 AM7:08 am Transgenomic reports Q1 EPS of ($0.10) vs ($0.28) year ago; revs -68.5% y/y to $236K (no estimates) -
05/24/16 06:07 AMQ1 2016 Transgenomic Inc Earnings Release - After Market Close -
05/23/16 03:06 PMTRANSGENOMIC INC Files SEC form 10-Q, Quarterly Report -
05/20/16 03:23 PMTransgenomic to Hold First Quarter 2016 Results Conference Call on May 24, 2016 at 9:00 AM EDT - [at noodls] - OMAHA, Neb. (May 20, 2016) - Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its First Quarter 2016 Financial Results and Business Update Conference Call on May 24, 2016 at ...
05/16/16 07:02 AMTransgenomic Study Data Shows 100% Concordance Between ICE COLD-PCR (ICP) Liquid Biopsies And Conventional Tissue Biopsy Results; ICP Also Identifies More Tumor Mutations Than Conventional Methods - [at noodls] - ICE COLD-PCR-Enriched Results Identify All Mutations Detected by Standard Tissue Biopsy PCR; ICP Also Identified Additional Mutations Missed by Conventional Tissue Biopsy Study Confirms ICE COLD-PCR's ...
05/16/16 06:30 AMTransgenomic Study Data Shows 100% Concordance between ICE COLD-PCR™ (ICP) Liquid Biopsies and Conventional Tissue Biopsy Results; ICP Also Identifies More Tumor Mutations Than Conventional Methods - [Business Wire] - Transgenomic, Inc. , today announced new concordance study data confirming the superior performance of its ICE COLD-PCR™ enrichment technology over standard biopsied tissue PCR results for detection of tumor mutations in cancer patients.
04/19/16 06:45 AMTransgenomic Unveils The First Rapid Turnaround Liquid Biopsy Metastatic Breast Cancer Panel At AACR 2016 Annual Meeting - [at noodls] - ICE COLD-PCR-Based Breast Cancer Analysis Panel Detects Mutations in Actionable PIK3CA and AKT1 Genes from Blood Samples at Sensitivity Down to 0.01%; Results Available in 10 Days Visit Booth #1356 at ...
04/15/16 10:49 AMEdited Transcript of TBIO earnings conference call or presentation 14-Apr-16 9:00pm GMT -
02/26/16 12:56 PMGermany Genetic Testing Market Outlook to 2021 Overview, Shares, Trends and Report Pertain to pharmacy Industry - Medgadget.com (blog) - Germany Genetic Testing Market Outlook to 2021 Overview, Shares, Trends and Report Pertain to pharmacy IndustryMedgadget.com (blog)GlobalDatas new report, “Germany Genetic Testing Market Outlook to 2021“, provides key market data on the Germany Genetic Testing market. The report provides value, in millions of US dollars within market segments – Acquired Gene or Chromosome ...and more »
02/26/16 05:28 AMTRANSGENOMIC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; -
01/26/16 08:39 AMTransgenomic Highlights Unique Advantages of Multiplexed ICE COLD-PCR at Personalized Medicine World Conference - [at noodls] - OMAHA, Neb. and MOUNTAIN VIEW, CA (January 26, 2016) - Transgenomic, Inc. (NASDAQ: TBIO) today announced that Ben Legendre, Jr., PhD, Vice President, Laboratory Operations, delivered a presentation yesterday ...
01/26/16 06:30 AMTransgenomic Highlights Unique Advantages of Multiplexed ICE COLD-PCR™ at Personalized Medicine World Conference - [Business Wire] - Transgenomic, Inc. today announced that Ben Legendre, Jr., PhD, Vice President, Laboratory Operations, delivered a presentation yesterday at the Personalized Medicine World Conference.
01/20/16 01:58 PMSHAREHOLDER ALERT -The Law Offices of Vincent Wong Launch an Investigation into Transgenomic Inc. - TBIO - [PR Newswire] - NEW YORK, Jan. 20, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Transgenomic Inc. (NASDAQCM: TBIO) in connection with possible ...
01/20/16 10:51 AMTRANSGENOMIC INC Files SEC form 8-K, Change in Directors or Principal Officers -
01/19/16 07:05 AMTransgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and PIK3CA Tumor Mutations - [at noodls] - Now Has Six Liquid Biopsy CLIA Cancer Panels that Leverage Exceptional Sensitivity of Multiplexed ICE COLD-PCR™ to Detect Actionable Mutations in RAS and PIK3CA Genes Relevant to Treatment of Lung and ...
01/14/16 11:24 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Transgenomic Inc. -- TBIO - [PR Newswire] - NEW YORK, Jan. 14, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Transgenomic Inc. (NASDAQCM: TBIO) concerning possible breaches of fiduciary duty by its Board of ...
01/11/16 07:08 AMTransgenomic Announces Private Placement Financing - [at noodls] - OMAHA, Neb. (January 11, 2016) - Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today ...
01/11/16 07:08 AMTransgenomic Announces Conversion of Series A and B Preferred Securities and Extension of Loan Maturity Date - [at noodls] - Simplified Capital Structure Provides Financial Flexibility for Broad Commercialization of ICE-COLD PCR™ in 2016 OMAHA, Neb. (January 11, 2016) - Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology ...
01/11/16 06:34 AMTRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti -
12/23/15 07:17 AMTransgenomic Awarded NIH Grant to Augment Multiplexing Capabilities of ICE COLD-PCR Technology in Collaboration with Dana-Farber Cancer Institute - [at noodls] - STTR Grant Supports Addition of Greater Multiplexing Capabilities to ICE COLD-PCR, an Advanced Technology that Enables Use of Tissue or Liquid Biopsy Samples and Provides Up to 500-Fold Increase in Mutation ...
12/23/15 06:30 AMTransgenomic Awarded NIH Grant to Augment Multiplexing Capabilities of ICE COLD-PCR™ Technology in Collaboration with Dana-Farber Cancer Institute - [Business Wire] - Transgenomic, Inc. , a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that it has been awarded a two-year Small Business Technology Transfer grant by the US National Institutes of Health .
12/21/15 04:06 PMTransgenomic Finalizes Divestment Of Its Genetic Assays & Platforms Business Unit - [at noodls] - Divestiture to ADSTEC Allows Transgenomic to Focus on Accelerating Commercialization of Its High Potential Multiplexed ICE COLD-PCR™ (MX-ICP) Technology OMAHA, Neb. (December 1, 2015) - Transgenomic, Inc. ...
12/21/15 04:06 PMTransgenomic Reports US Insurers Covering More Than 110 Million Lives Are Providing Reimbursement For Its Genomic Cancer Tests - [at noodls] - The Number of Covered Individuals is Expected to Increase by More than 50 Million in 2016 OMAHA, Neb. (December 9, 2015) - Transgenomic, Inc. (NASDAQ: TBIO) today reported on the status of insurance reimbursement ...
12/08/15 12:18 PMTRANSGENOMIC INC Financials -
12/02/15 11:23 AMTransgenomic, Inc. Earnings Q3, 2015 -
12/01/15 06:31 AMTRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposi -
About Transgenomic

Transgenomic logoTransgenomic, Inc. is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Scientific & Technical Instruments
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBIO
  • CUSIP:
Key Metrics:
  • Previous Close: $0.57
  • 50 Day Moving Average: $0.5940
  • 200 Day Moving Average: $0.6853
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $11.74M
  • Current Quarter EPS Consensus Estimate: $-1.4500 EPS
Additional Links:
Transgenomic (NASDAQ:TBIO) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha